Curative Ventures V LLC
Long book
$15.6M
Q1 2026
Positions
1
Top-10 weight
100%
concentration
Last quarter
-25.1%
SPY -4.4%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsCurative Ventures V LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $15.6M US long book across 1 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: Instil Bio, Inc..
Over the last 8 quarters its long book ran on average 48.2pp per quarter ahead of the S&P 500, beating the index in 2 of 8 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-4.7%
Q2 2024
+554.2%
Q3 2024
-71.6%
Q4 2024
-9.1%
Q1 2025
+20.0%
Q2 2025
-14.3%
Q3 2025
-38.4%
Q4 2025
-25.1%
Sector allocation
Healthcare 100%
Long book by quarter
What does Curative Ventures own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| TIL Instil Bio, Inc. | Healthcare | 1.9M | $15.6M | 100.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | Apr 29, 2026 | 1 | $15.6M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 3, 2026 | 1 | $20.9M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 3, 2025 | 1 | $33.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 29, 2025 | 1 | $39.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | Apr 30, 2025 | 1 | $33.0M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Jan 29, 2025 | 1 | $36.3M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Oct 31, 2024 | 1 | $127.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Jul 17, 2024 | 1 | $19.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 8, 2024 | 1 | $20.5M | canonical | SEC ↗ |